Analyzing the correlation between CRIP1 and PD-L1 expression in different tumors, studying the clinical association between CRIP1 and PD-L1, and combining CRIP1-targeted therapy and anti-PD-L1 therapy may provide new ideas for tumor immunotherapy. This evidence concerns the gene CD274 and neoplasm.